JP6724009B2 - 抗ｃｄ７０キメラ抗原受容体 - Google Patents

抗ｃｄ７０キメラ抗原受容体 Download PDF

Info

Publication number
JP6724009B2
JP6724009B2 JP2017530742A JP2017530742A JP6724009B2 JP 6724009 B2 JP6724009 B2 JP 6724009B2 JP 2017530742 A JP2017530742 A JP 2017530742A JP 2017530742 A JP2017530742 A JP 2017530742A JP 6724009 B2 JP6724009 B2 JP 6724009B2
Authority
JP
Japan
Prior art keywords
car
amino acid
cell
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017530742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505139A (ja
JP2018505139A5 (https=
Inventor
ジェイ． ワン、チョン
ジェイ． ワン、チョン
ユ、ジヤ
シー． ヤン、ジェームズ
シー． ヤン、ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2018505139A publication Critical patent/JP2018505139A/ja
Publication of JP2018505139A5 publication Critical patent/JP2018505139A5/ja
Application granted granted Critical
Publication of JP6724009B2 publication Critical patent/JP6724009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2017530742A 2014-12-08 2015-04-09 抗ｃｄ７０キメラ抗原受容体 Active JP6724009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088882P 2014-12-08 2014-12-08
US62/088,882 2014-12-08
PCT/US2015/025047 WO2016093878A1 (en) 2014-12-08 2015-04-09 Anti-cd70 chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020109158A Division JP7128860B2 (ja) 2014-12-08 2020-06-24 抗ｃｄ７０キメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2018505139A JP2018505139A (ja) 2018-02-22
JP2018505139A5 JP2018505139A5 (https=) 2018-05-24
JP6724009B2 true JP6724009B2 (ja) 2020-07-15

Family

ID=52997584

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017530742A Active JP6724009B2 (ja) 2014-12-08 2015-04-09 抗ｃｄ７０キメラ抗原受容体
JP2020109158A Active JP7128860B2 (ja) 2014-12-08 2020-06-24 抗ｃｄ７０キメラ抗原受容体
JP2022092594A Active JP7574243B2 (ja) 2014-12-08 2022-06-07 抗ｃｄ７０キメラ抗原受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020109158A Active JP7128860B2 (ja) 2014-12-08 2020-06-24 抗ｃｄ７０キメラ抗原受容体
JP2022092594A Active JP7574243B2 (ja) 2014-12-08 2022-06-07 抗ｃｄ７０キメラ抗原受容体

Country Status (12)

Country Link
US (3) US10689456B2 (https=)
EP (3) EP3230310B1 (https=)
JP (3) JP6724009B2 (https=)
CN (2) CN107207616B (https=)
AU (3) AU2015361261B2 (https=)
CA (1) CA2970280A1 (https=)
DK (1) DK3597663T3 (https=)
ES (2) ES2745153T3 (https=)
PL (1) PL3230310T3 (https=)
PT (1) PT3230310T (https=)
SI (1) SI3230310T1 (https=)
WO (1) WO2016093878A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022137020A (ja) * 2014-12-08 2022-09-21 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105949325B (zh) * 2016-07-08 2019-07-16 重庆精准生物技术有限公司 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用
WO2018027197A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
US11788093B2 (en) 2017-09-07 2023-10-17 University Of Florida Research Foundation, Inc. Chimeric antigen receptor t-cells expressing interleukin-8 receptor
GB201720949D0 (en) * 2017-12-15 2018-01-31 Autolus Ltd Cell
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
MX2020012028A (es) * 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
IL311860A (en) * 2018-08-02 2024-06-01 Kite Pharma Inc Treatment with receptor-antigen chimeric kinetics of T cell expansion and their uses
CN109880802B (zh) * 2018-11-30 2022-12-13 北京美康基免生物科技有限公司 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN114025775A (zh) * 2019-04-30 2022-02-08 纪念斯隆-凯特琳癌症中心 联合疗法
US20200384278A1 (en) * 2019-06-04 2020-12-10 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Method for Combination Cold Atmospheric Plasma and CAR-T Therapy
EP4031150A4 (en) * 2019-09-16 2023-11-01 The General Hospital Corporation CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF
CA3166832A1 (en) * 2020-01-08 2021-07-15 Board Of Regents, The University Of Texas Systems A method of engineering natural killer cells to target cd70-positive tumors
CN111909966B (zh) * 2020-04-01 2021-09-21 苏州克睿基因生物科技有限公司 一种制备经修饰的免疫细胞的方法
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022116952A1 (zh) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 靶向cd70的抗原结合蛋白及其应用
WO2022129216A1 (en) 2020-12-15 2022-06-23 Universiteit Antwerpen Cell-based therapeutics targeting cd70
WO2022159791A1 (en) * 2021-01-25 2022-07-28 Board Of Regents, The University Of Texas System Cd27-extracellular domain car to target cd70-positive tumors
US20220378829A1 (en) * 2021-05-12 2022-12-01 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2023072307A1 (zh) * 2021-10-25 2023-05-04 重庆精准生物技术有限公司 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用
US20250255960A1 (en) * 2022-01-19 2025-08-14 Hrain Biotechnology Co., Ltd. Anti-cd70 nanoantibody and use thereof
KR20250004736A (ko) * 2022-04-07 2025-01-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조작된 자연 살해 세포의 활성화 및 증대 및 항체와의 조합을 위한 방법
CN117126856A (zh) * 2022-05-20 2023-11-28 上海雅科生物科技有限公司 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504186A (ja) 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション Ｃｄ５３細胞表面抗原とその使用
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
MX2013004792A (es) * 2010-10-27 2013-08-27 Baylor College Medicine Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA2832540C (en) * 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
ES2654060T3 (es) * 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
IL238323B2 (en) * 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
EP3230310B1 (en) * 2014-12-08 2019-06-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd70 chimeric antigen receptors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022137020A (ja) * 2014-12-08 2022-09-21 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体
JP7574243B2 (ja) 2014-12-08 2024-10-28 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体

Also Published As

Publication number Publication date
US20180208671A1 (en) 2018-07-26
AU2015361261B2 (en) 2020-03-12
CN113968913A (zh) 2022-01-25
DK3597663T3 (da) 2022-06-27
US10689456B2 (en) 2020-06-23
US20200317807A1 (en) 2020-10-08
JP7574243B2 (ja) 2024-10-28
CA2970280A1 (en) 2016-06-16
PT3230310T (pt) 2019-09-26
JP2020171292A (ja) 2020-10-22
EP3230310B1 (en) 2019-06-12
ES2921208T3 (es) 2022-08-19
US11999796B2 (en) 2024-06-04
WO2016093878A1 (en) 2016-06-16
AU2021277627A1 (en) 2021-12-23
AU2021277627B2 (en) 2023-08-24
AU2020203836B2 (en) 2021-09-09
AU2015361261A1 (en) 2017-06-15
EP3597663B1 (en) 2022-04-06
JP2022137020A (ja) 2022-09-21
JP2018505139A (ja) 2018-02-22
SI3230310T1 (sl) 2019-11-29
EP3597663A1 (en) 2020-01-22
ES2745153T3 (es) 2020-02-27
JP7128860B2 (ja) 2022-08-31
EP3230310A1 (en) 2017-10-18
PL3230310T3 (pl) 2020-02-28
CN107207616B (zh) 2021-11-19
AU2020203836A1 (en) 2020-07-02
EP4043487A1 (en) 2022-08-17
CN107207616A (zh) 2017-09-26
US20240294665A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
JP7574243B2 (ja) 抗ｃｄ７０キメラ抗原受容体
KR102841067B1 (ko) Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체
EP3448882B1 (en) Anti-kk-lc-1 t cell receptors
AU2016338747A1 (en) Anti-CD30 chimeric antigen receptors
HK40021099B (en) Anti-cd70 chimeric antigen receptors
HK40021099A (en) Anti-cd70 chimeric antigen receptors
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
EP4612169A1 (en) Hla-a3-restricted t cell receptors against braf with v600e mutation
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20170901

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20170901

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180405

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200624

R150 Certificate of patent or registration of utility model

Ref document number: 6724009

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250